For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial res...

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. ...

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How shou...

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of pr...

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will di...